What is BPC-157? The Body Protection Compound Explained
A comprehensive research guide to BPC-157 — its structure, mechanism, research vectors and comparison with TB-500.
BPC-157 (Body Protection Compound 157) is one of the most extensively researched peptides in the regenerative biology space. A synthetic pentadecapeptide derived from a protective protein found in gastric juice, it has become a cornerstone compound in tissue repair, angiogenesis, and wound tissue remodelling research models.
What is BPC-157?
BPC-157 is a 15 amino acid peptide (pentadecapeptide) derived from a sequence found in human gastric juice. Its full designation is Body Protection Compound-157, referencing its origin in the body’s natural gastrointestinal protective mechanisms.
What makes BPC-157 particularly interesting as a research compound is its remarkable stability compared to endogenous peptides. It remains active in the presence of gastric acid and shows resistance to enzymatic degradation, making it a practical subject for a wide range of laboratory models.
Mechanism of Action
BPC-157 operates through several interconnected pathways that make it a multi-vector research compound:
- Angiogenesis: BPC-157 is studied for its ability to upregulate VEGF (vascular endothelial growth factor) expression, stimulating the formation of new blood vessels — a critical component of tissue repair models.
- Nitric Oxide Synthesis: Research suggests BPC-157 modulates the NO system, which plays a role in vasodilation, cellular signalling, and tissue homeostasis.
- Growth Factor Upregulation: Studies indicate interactions with growth hormone receptor expression, potentially amplifying local growth factor activity at wound sites.
- Tendon and Ligament Research: BPC-157 has been studied extensively in models of tendon and ligament repair, with research focusing on tenocyte proliferation and collagen synthesis.
- Gut Protective Mechanisms: Given its gastric origin, BPC-157 is researched in models of inflammatory bowel disease and intestinal barrier integrity.
BPC-157 Research Applications
Musculoskeletal Research
BPC-157 is one of the most studied peptides in models of muscle, tendon and ligament tissue. Research has explored its interactions with the extracellular matrix and its potential to modulate fibroblast activity in injury models.
Angiogenic Research
The compound’s effect on VEGF and nitric oxide pathways makes it a useful tool in studying vascular formation and blood supply to tissue remodelling tissue — a critical limiting factor in wound tissue remodelling models.
Gastrointestinal Research
Derived from gastric protective proteins, BPC-157 has a well-documented research history in gut inflammation models, including studies on intestinal fistulas and inflammatory bowel conditions.
Neurological Research
More recent research has explored BPC-157’s interaction with dopaminergic and serotonergic systems, making it a subject of interest in neuroscience research models.
BPC-157 Data Sheet
| Parameter | Value |
|---|---|
| Sequence Length | 15 Amino Acids |
| Molecular Class | Synthetic Pentadecapeptide |
| Format | Lyophilized |
| Stability | High (acid/enzyme resistant) |
| Key Pathways | VEGF, NO System, GHR |
| Storage (Dry) | Cool, dark, low humidity |
| Storage (Reconstituted) | 2°C – 8°C |
| Research Use | In-vitro only |
BPC-157 in Composite Research Stacks
BPC-157 is frequently studied in combination with other peptides to investigate synergistic effects. Common composite stacks featuring BPC-157 include:
- Wolverine Blend (BPC-157 + TB-500): The most common combination in tissue repair research, pairing BPC-157’s local angiogenic effects with TB-500’s systemic cellular migration properties.
- TR-3 (TB-500 + BPC-157 + KPV): A tri-peptide stack adding the anti-inflammatory KPV tripeptide for studies requiring concurrent cytokine modulation.
- GLOW 70 (GHK-Cu + BPC-157 + TB-500): A skin and tissue focused composite for advanced dermal regeneration research.
- KLOW 80 (GHK-Cu + BPC-157 + TB-500 + KPV): The most comprehensive of these regenerative stacks.
Compound Profile
| Property | Detail |
|---|---|
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV) |
| Molecular formula | C62H98N16O22 |
| Molecular weight | 1419.5 g/mol |
| CAS number | 137525-51-0 |
| Origin | Partial sequence of “body protection compound”, a protein isolated from human gastric juice by Sikirić and colleagues in Zagreb in the early 1990s |
| Human data | One two-participant intravenous safety pilot (2025); no controlled efficacy trials published |
| Regulatory status | Not an approved medicine in the UK, EU or US. Prohibited in sport at all times (WADA class S0) |
Key Published Research
Most BPC-157 evidence comes from rodent and cell models. These are among the most frequently cited studies:
- Tendon healing mechanisms (2011): In rat Achilles tendon explants and tendon fibroblasts, BPC-157 increased tendon outgrowth, protected cells under oxidative stress and promoted fibroblast migration through FAK–paxillin signalling.1
- Growth hormone receptor (2014): The same group reported increased growth hormone receptor expression in tendon fibroblasts — the source of the “GHR” pathway often listed for this peptide.2
- Angiogenesis via VEGFR2 (2017): BPC-157 up-regulated and activated VEGFR2, switching on VEGFR2–Akt–eNOS signalling in endothelial cells, and accelerated blood-flow recovery in a rat hind-limb ischaemia model.3
- Musculoskeletal review (2019): A review of tendon, ligament, muscle and bone studies found consistently positive animal data while noting the absence of human trials.4
- Gut–brain axis (2023): The originating Zagreb group’s review summarises BPC-157’s studied effects across gastrointestinal, vascular and central nervous system models.5
- First human safety data (2025): An ethics-approved pilot gave intravenous BPC-157 to two healthy adults and reported no adverse effects on the vital signs and blood markers measured, with plasma levels returning to baseline within 24 hours.6
Regulatory & Research Status (2026)
- April 2026 — FDA Category 2 removal: The US FDA removed BPC-157, with eleven other peptides, from its Category 2 list of bulk substances raising significant safety concerns. This is not an approval — BPC-157 was not moved to the list of substances permitted for compounding.
- July 2026 — advisory committee vote: The FDA’s Pharmacy Compounding Advisory Committee voted 8–6 (one abstention) in favour of adding BPC-157 to the 503A bulks list for a proposed ulcerative colitis use. The vote is non-binding: FDA reviewers had recommended against, citing insufficient characterisation and safety data, and any change would follow formal rulemaking.
- 2025 literature reviews: A literature and patent review and a musculoskeletal narrative review both concluded that the preclinical findings are extensive but that controlled human studies and long-term safety data are still lacking.7,8
- Sport: BPC-157 remains prohibited at all times on the 2026 WADA Prohibited List.
Evidence Quality & Limitations
BPC-157 has a large literature, but three caveats matter when designing or interpreting research. First, a large share of published studies come from a single research group, and independent replication is comparatively limited. Second, almost all data are from rodent models using widely varying routes, doses and endpoints, which makes cross-study comparison difficult. Third, the mechanistic picture — VEGF, nitric oxide, FAK–paxillin and growth hormone receptor signalling — rests largely on in-vitro and animal work. Confirm the identity and purity of every batch by HPLC and mass spectrometry before use.
References
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110:774–80. PubMed
- Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19:19066–77. PubMed
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95:323–33. PubMed
- Gwyer D, et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377:153–9. PubMed
- Sikirić P, et al. Stable gastric pentadecapeptide BPC 157 may recover brain–gut axis and gut–brain axis function. Pharmaceuticals. 2023;16. PubMed
- Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31:20–4. PubMed
- Józwiak M, et al. Multifunctionality and possible medical application of the BPC 157 peptide — literature and patent review. Pharmaceuticals. 2025;18:185. PubMed
- McGuire FP, et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025;18:611–9. PubMed
